, link1: Mult Scler. 2008 Jun;14(5):708-10. Links
Paradoxically aggressive multiple sclerosis in the face of natalizumab therapy.Berger JR.
Department of Neurology, University of Kentucky College of Medicine, 740 S. Limestone Street, Lexington, KY 40536, USA. firstname.lastname@example.org
In the pivotal trials of natalizumab in the treatment of relapsing-remitting multiple sclerosis (AFFIRM and SENTINEL), a dramatic reduction in relapse rate, new or enlarging T2-hyperintense lesions, and mean number of gadolinium-enhancing lesions was observed. While both relapses and new MRI lesions were observed in these trials, there has been no comment on the presence of aggressive disease in the face of natalizumab treatment. I report a 31-year-old woman with relapsing remitting MS of 12 years duration who developed aggressive demyelinating disease four months after the initiation of natalizumab. The clinical worsening was accompanied by a significant increase in new large T2-hyperintense signal abnormalities and in both solid and C-shaped contrast-enhancing lesions. Neither the clinical severity nor the striking MRI abnormalities had been noted earlier in her disease course. Neutralizing antibodies to natalizumab were not detected. She subsequently responded to combination therapy of pulsed methylprednisolone and daily glatiramer acetate.
cheerleader wrote:The virus has been found in spinal fluid of MS patients (before drugs):
and it uses Seratonin receptors to infect cells in the brain:
http://www.sciencemag.org/cgi/content/a ... 380?ck=nck
I just don't understand how a drug company can continue to test Tysabri on an unsuspecting population of folks who may very well have the JC virus in their bodies activated to PML!!!!
paul2008 wrote:just in time.....was about to start the drug but have now definitely changed my mind. It's not been around long enough and as they say themselves expect more cases of PML. Think I'll stick with Rebif and steroids for the moment.
NOT treating multiple sclerosis, or not treating MS effectively carries it's own risks, which seems to carry more risk than Tysabri use.
Users browsing this forum: Scott1